200 related articles for article (PubMed ID: 17127203)
1. Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy.
Strangfeld A; Listing J
Best Pract Res Clin Rheumatol; 2006 Dec; 20(6):1181-95. PubMed ID: 17127203
[TBL] [Abstract][Full Text] [Related]
2. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.
Winthrop KL
Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599
[TBL] [Abstract][Full Text] [Related]
3. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.
Salmon-Ceron D; Tubach F; Lortholary O; Chosidow O; Bretagne S; Nicolas N; Cuillerier E; Fautrel B; Michelet C; Morel J; Puéchal X; Wendling D; Lemann M; Ravaud P; Mariette X;
Ann Rheum Dis; 2011 Apr; 70(4):616-23. PubMed ID: 21177290
[TBL] [Abstract][Full Text] [Related]
4. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy.
Kroesen S; Widmer AF; Tyndall A; Hasler P
Rheumatology (Oxford); 2003 May; 42(5):617-21. PubMed ID: 12709536
[TBL] [Abstract][Full Text] [Related]
5. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.
Salliot C; Gossec L; Ruyssen-Witrand A; Luc M; Duclos M; Guignard S; Dougados M
Rheumatology (Oxford); 2007 Feb; 46(2):327-34. PubMed ID: 16880188
[TBL] [Abstract][Full Text] [Related]
6. [Infectious risk].
Calabuig E; Salavert M
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
8. [Non tuberculous anti-TNF associated opportunistic infections].
Marie I; Guglielmino E
Rev Med Interne; 2010 May; 31(5):353-60. PubMed ID: 20381217
[TBL] [Abstract][Full Text] [Related]
9. [Rheumatology. TNF alpha-inhibitors: infection risks? Practical recommendations].
Faucherre M; Pazar B; So A; Aubry-Rozier B
Rev Med Suisse; 2011 Jan; 7(277):75-6, 78-9. PubMed ID: 21309182
[TBL] [Abstract][Full Text] [Related]
10. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications?
Kawakami K; Ikari K; Kawamura K; Tsukahara S; Iwamoto T; Yano K; Sakuma Y; Tokita A; Momohara S
Rheumatology (Oxford); 2010 Feb; 49(2):341-7. PubMed ID: 19965973
[TBL] [Abstract][Full Text] [Related]
11. Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.
Downey C
Int J Rheum Dis; 2016 Jun; 19(6):536-50. PubMed ID: 26200188
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection.
Furst DE; Wallis R; Broder M; Beenhouwer DO
Semin Arthritis Rheum; 2006 Dec; 36(3):159-67. PubMed ID: 16884970
[TBL] [Abstract][Full Text] [Related]
13. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
Leombruno JP; Einarson TR; Keystone EC
Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
[TBL] [Abstract][Full Text] [Related]
14. Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice.
Neven N; Vis M; Voskuyl AE; Wolbink GJ; Nurmohamed MT; Dijkmans BA; Lems WF
Ann Rheum Dis; 2005 Apr; 64(4):645-6. PubMed ID: 15769924
[No Abstract] [Full Text] [Related]
15. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.
Moiton MP; Richez C; Dumoulin C; Mehsen N; Dehais J; Schaeverbeke T
Clin Microbiol Infect; 2006 Dec; 12(12):1151-3. PubMed ID: 17121619
[TBL] [Abstract][Full Text] [Related]
16. Two cases of serious food-borne infection in patients treated with anti-TNF-alpha. Are we doing enough to reduce the risk?
Makkuni D; Kent R; Watts R; Clunie G
Rheumatology (Oxford); 2006 Feb; 45(2):237-8. PubMed ID: 16377730
[No Abstract] [Full Text] [Related]
17. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}.
Winthrop KL
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv29-30. PubMed ID: 16239382
[No Abstract] [Full Text] [Related]
18. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
[TBL] [Abstract][Full Text] [Related]
19. The risk of infections with biologic therapies for rheumatoid arthritis.
Furst DE
Semin Arthritis Rheum; 2010 Apr; 39(5):327-46. PubMed ID: 19117595
[TBL] [Abstract][Full Text] [Related]
20. [Infectious risks of immunomodulating therapies in rheumatology].
Van Delden C
Rev Med Suisse; 2006 Mar; 2(57):738-40, 743-5. PubMed ID: 16604876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
